ArticleFrontiers in immunology2025

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade.

Przemysław Bielski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.